Comparing 1 hypotheses side-by-side
We hypothesize that pathological tau's abnormal interaction with the ESCRT machinery for exosomal release is driven by site-specific loss of O-GlcNAcylation at T212, which normally prevents phosphorylation at nearby sites (S214, S262) that enhance TSG101/ESCRT-I binding. In normal states, O-GlcNAcylation at T212 competes with these pro-aggregation phosphorylations, limiting tau's engagement with ESCRT components and preventing pathological secretion. In disease states, reduced O-GlcNAcytransfera
| Dimension | O-GlcNAcylation at T212 compet |
|---|---|
| Mechanistic | 0.000 |
| Evidence | 0.650 |
| Novelty | 0.780 |
| Feasibility | 0.720 |
| Impact | 0.000 |
| Druggability | 0.000 |
| Safety | 0.000 |
| Competition | 0.000 |
| Data | 0.000 |
| Reproducible | 0.000 |
| KG Connect | 0.500 |
No evidence citations yet
4 rounds · quality: 0.95
Based on the knowledge gap regarding selective targeting of tau-containing vesicles, here are 7 novel therapeutic hypotheses: ## Hypothesis 1: Tau Conformational State-Specific Nanobody Targeting **D...
I'll provide a rigorous critique of each hypothesis, identifying weaknesses and gaps in the evidence. Let me analyze these systematically: ## Hypothesis 1: Tau Conformational State-Specific Nanobody ...
**Druggability Assessment:** - **Target**: HSP70/HSP90-MAPT interaction modulation - **Precedent**: HSP90 inhibitors extensively developed (17-AAG, ganetespib) - **Challenge**: Achieving selectivity f...
```json { "ranked_hypotheses": [ { "title": "Autophagosome Marker Hijacking Strategy", "description": "Design therapeutics that mimic or enhance LC3-tau interactions to redirect tau-...